Targeted α-particle therapy of microscopic disease: Providing a further rationale for clinical investigation

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1238-1240

  Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOGEN; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX35 AT 211; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ALPHA RADIATION; CANCER SIZE; CARCINOMATOUS MENINGITIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DOSIMETER; DRUG EFFICACY; DRUG HALF LIFE; ELECTRON THERAPY; HUMAN; MEDICAL LITERATURE; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; MONTE CARLO METHOD; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PUBLICATION; RADIATION DOSE; RADIOACTIVITY; RECURRENT CANCER; SCANNING ELECTRON MICROSCOPY; SHORT SURVEY; TREATMENT OUTCOME; ANIMAL; CANCER TRANSPLANTATION; CLINICAL TRIAL; FEMALE; METHODOLOGY; MOUSE; NEOPLASM; NOTE; NUDE MOUSE; OVARY TUMOR; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 33749042579     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Des. 2000;6:1433-1455.
2. 131I-labeled monoclonal antibodies? Some dosimetric considerations. Recent Results Cancer Res. 1996;141:67-75.
3. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-1497.
4. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl):199S-204S.
5. 211At] astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994;54:5414-5419.
6. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218-225.
7. 211At]astatobenzoate synthesis. J Nucl Med. 2005;46:1393-1400.
8. Elgqvist J, Andersson H, Bäck T, et al. α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342-1350.
9. 211At-labelled monoclonal antibody MOv18. Anticancer Res. 2000;20:459-462.
10. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: a long term study. Acta Oncol. 2000;39:741-745.
11. 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian carcinoma. Anticancer Res. 2001;21:409-412.
12. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9(suppl):3914S-3921S.
13. 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-1915.
14. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Des. 2000;6:1433-1455.
15. Welshinger M, Yin BWT, Lloyd KO. Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecol Oncol. 1997;67:188-192.
16. 90Y. Int J Radiat Oncol Biol Phys. 1984;10:341-348.